Colorectal cancer risk in ulcerative colitis: an updated population-based systematic review and meta-analysis
A partir d'une revue systématique de la littérature publiée jusqu'en avril 2025 (13 études, 161 157 patients), cette méta-analyse évalue le risque de cancer colorectal chez des patients atteints d'une rectocolite hémorragique
Background: Patients with ulcerative colitis (UC) face a heightened risk of colorectal cancer (CRC), though the estimated risk levels differ across UC populations. This study aims to provide updated, population-based estimates of CRC incidence, standardised incidence ratios (SIR), and prevalence in patients with UC.
Methods: We searched PubMed, Embase, and Cochrane Library to April 12, 2025, for population-based studies on patients with UC reporting CRC risk. Study quality was assessed using the Newcastle–Ottawa Scale. The primary outcome was CRC risk in UC, evaluated through incidence, SIR, and prevalence. A random-effects model was used for meta-analysis, and meta-regression evaluated the impact of study characteristics. Publication bias was assessed using funnel plots and statistical tests. PROSPERO: CRD42025634800.
Findings: From 7991 records, 13 population-based studies involving 161,157 patients with UC were included. Most studies were conducted in Europe, with others from North America and Asia. All studies were of good quality, with scores greater than 5 on the NOS quality assessment scale. The pooled CRC incidence was 1.47 per 1000 person-years (95% CI 1.30–1.67; I2 = 66.2%), the SIR was 2.48 (95% CI 1.64–3.76; I2 = 91.7%), and the prevalence was 1.54% (95% CI 1.14–1.99; I2 = 96.1%). Subgroup analyses revealed similar CRC risk in male (SIR 2.14, 95% CI 0.85–5.38) and female (SIR 2.20, 95% CI 1.52–3.19) patients and an increased risk with extensive colitis, with an SIR of 3.95 (95% CI 2.56–6.09).
Interpretation: This systematic review and meta-analysis provides population-based estimates of CRC risk in patients with UC, based on high-quality studies with rigorous methodology. The results offer reliable reference values for incidence, SIR, and prevalence, which are applicable to the broader UC population and relevant to clinical decision-making and public health planning. Nonetheless, substantial heterogeneity across studies and limited geographic representation—particularly from Asia, South America, Africa, and Oceania—highlight the need for additional population-based research in underrepresented regions to improve the global applicability of CRC risk estimates in UC..
eClinicalMedicine , article en libre accès, 2025